New York Providers Prescribing Compounded Ketamine to Patients Should Be Aware of the October 10 2023 FDA Alert

The only psychedelic substance which can be prescribed by New York providers at this time is ketamine (for off-label use) and Spravato (which only includes the esketamine molecule). While Spravato has been approved by the FDA for treatment of depression, ketamine is not currently FDA approved for such treatment. New York providers are prescribing compounded ketamine to their patients.

Providers offering compounded ketamine to patients should be aware of this FDA alert published on October 10, 2023 (FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders | FDA)